CNS Drug News Issue - CNS Breakthroughs Slowing Despite Increasing Demand - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "CNS Drug News Issue 374" report to their offering.

Rising burdens of disease will continue to drive CNS research even as the pace of development slows due to the high costs of development and risks of trial failure. Demographic change and significant unmet need will maintain blockbuster potential for a range of disorders, but breakthroughs will remain rare due to poorly understood pathology and a lack of biomarkers. A focus on fundamental research in the area will revitalise pipelines, however, this will leave a significant deficit in near-term CNS pipelines.

Key Topics Covered:

1. Neurodegenerative Disorders

  • Parkinson's Disease
  • Zambon Launches Xadago In Italy For Patients With Parkinson's Disease
  • Alzheimer's Disease
  • Lilly Reports Primary Endpoint Change In Solanezumab Phase III AD Study
  • Multiple Sclerosis
  • Defensive Moves Cannot Forestall Copaxone's Generic Losses For Long
  • Opexa Initiates Restructuring To Focus Use Of Resources
  • Narrowing Trials Reduces Expenditure But Increases Risks For Arzerra
  • Other Neurodegenerative Disorders
  • FDA ODD For Biohaven's BHV-0223 To Treat SCA
  • FDA ODD For AstraZeneca's MEDI-551 To Treat NMO/NMOSD

2. Antidepressants

  • Adjunctive Benefits Targeted To Drive Rexulti Sales Growth
  • Minerva Reports Positive Top-Line Data From MIN-202 Phase Ib MDD Trial

3. Psychotic Disorders

  • Abilify Approved In Japan For Administration At Deltoid Muscle Site
  • SPI Enters Research Collaboration For Bipolar Disorder

4. Analgesics/Anaesthetics

  • FDA Accepts Egalet's Arymo NDA For Review
  • Sublingual Delivery Focus Will Underscore AcelRx's Performance
  • New US Approvals For Hikma
  • Xenon/ Genentech Extend Pain Genetics Research Collaboration

5. Drugs used in Nausea & Vertigo

  • Specialized Therapeutics/Mundipharma Enter Sublicensing Deal For Anti-Emetic Products

6. General Development News

  • AstraZeneca/ProStrakan Enter Deal For Moventig In Europe

7. Corporate Activity

  • Alexza Enters Non-Binding Letter Of Intent With Grupo Ferrer

8. Conference Listings

For more information visit http://www.researchandmarkets.com/research/m2x966/cns_drug_news

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System Drugs